Generic drugs in Singapore are registered through the Health Sciences Authority (HSA). Applicants must submit a dossier demonstrating bioequivalence to the reference product, ensuring safety, efficacy, and quality. The HSA reviews the application, and upon approval, the generic drug is listed in... Read More
The Singapore Standard for Pharmaceutical Product Quality is governed by the Health Sciences Authority (HSA), which ensures compliance with international standards like the International Council for Harmonisation (ICH) guidelines. It mandates rigorous quality control, safety, and efficacy assessments, aligning with Good Manufacturing... Read More
Biologics in Singapore are registered through the Health Sciences Authority (HSA). The process involves submitting a New Drug Application (NDA) with comprehensive data on quality, safety, and efficacy. Evaluation includes scientific assessment and Good Manufacturing Practice (GMP) compliance. Successful applications receive marketing... Read More
In Singapore, high-risk drugs undergo a stringent evaluation by the Health Sciences Authority (HSA). The process includes pre-submission consultations, scientific assessments, and clinical data reviews. The HSA ensures safety, efficacy, and quality through rigorous testing and post-market surveillance, adhering to international standards... Read More
Singapore handles orphan drug registration through the Health Sciences Authority (HSA), which offers a special Orphan Drug Designation pathway. This process provides regulatory support and incentives, such as fee waivers and expedited review, to encourage the development and availability of treatments for... Read More
Clinical trial data is crucial for registering drugs in Singapore as it provides evidence of safety, efficacy, and quality. The Health Sciences Authority (HSA) evaluates this data to ensure that new drugs meet regulatory standards, protecting public health and ensuring that therapeutic... Read More
Yes, pharmacovigilance requirements are integral to drug registration in Singapore. The Health Sciences Authority mandates a risk management plan and ongoing safety monitoring. Companies must report adverse drug reactions and submit periodic safety update reports to ensure drug safety and efficacy throughout... Read More
Confidentiality during drug registration in Singapore is maintained through strict regulatory frameworks. The Health Sciences Authority (HSA) enforces data protection protocols, ensuring sensitive information is accessible only to authorized personnel. Secure electronic submission systems and confidentiality agreements further safeguard proprietary data, preventing... Read More
Common reasons for rejection of drug registration applications in Singapore include insufficient clinical data, inadequate safety and efficacy evidence, poor manufacturing practices, non-compliance with regulatory guidelines, incomplete documentation, labeling inaccuracies, and lack of bioequivalence studies. These factors can lead to concerns about... Read More
In Singapore, combination products are registered through the Health Sciences Authority (HSA). Applicants must determine the primary mode of action to classify the product as a drug, device, or biologic. The appropriate regulatory framework is then followed, involving submission of relevant documentation,... Read More